Published Date : May 22, 2017
ALBANY, New York, May 22, 2017 - MarketResearchReports.biz has announced the addition of the report titled, “Global Anticoagulants Market: Size, Trends & Forecasts 2017 - 2021,” to their offering. The report furnishes crucial information about the market such as its size, the competitive landscape, and its growth prospects going forward. The report finds that the market has expanded at a healthy clip over the years.
Anticoagulants, also referred to as blood thinners, are drugs meant to thwart blood from clotting or prevent existing ones from getting larger. The drugs help in stopping formation of clots in heart, veins or arteries, which be dangerous at times and can even lead to heart attack or stroke. Hence, anticoagulants find application in treating strokes, pulmonary embolisms, myocardial infarctions, disseminated intravascular coagulation (DIC), and deep vein thrombosis (DVT). All the aforementioned can prove fatal.
The report finds that the burgeoning geriatric population highly susceptible to heart diseases, high instances of coagulation disorders, growing awareness about anticoagulant and the resultant demand for novel oral anticoagulants (NOAC), higher instances of coagulation disorders, alarming instances of atrial fibrillation, and pressing need to bring down healthcare costs have been driving growth in the global anticoagulants market. The report forecasts the market to see a steady upswing in the next couple of years, especially due to NOACs.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/1068332
Countering the growth in the global anticoagulant market is the steep price of NOACs and dearth of antidotes for them, strict rules, and side effects resulting from the usage of the drugs. At present, the market is witnessing trends such as expanding therapeutic applications of the drugs and various patient assistance programs.
Warfarin is the most commonly prescribed anticoagulant. However, newer varieties of anticoagulants in the form of capsules and tablets are also seeing swift uptake. Rivaroxaban (Xarelto), edoxaban (Savaysa/Lixiana), dabigatran (Pradaxa), and apixaban (Eliquis) are to name a few of them. Heparin, another form of anticoagulant, can be administered in the form of injection too. The report studies each of the anticoagulants to understand their sales and revenues, market shares, and market prospects in the near future.
Having shed light on the growth drivers, restraints, and current market trends and the different products available in the anticoagulants market, the report goes on to discuss the market in the U.S. It studies the market for each of the drugs, namely Savaysa, Xarelto, Pradaxa, and Eliquis, in the region.
Some of the key players in the global anticoagulant market that have been profiled in the report are Bayer Group, Boehringher Ingelheim, BMS/Pfizer, and Daiichi Sankyo. The report throws light on their product offerings, sales and revenues, key strategies, market shares, and growth trajectory going forward. The report finds that most of the keen players are opting for strategic alliances to bolster their positions.
To order report Call Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org